13F filing recap · Q3 2010

What did ValueAct Capital buy in Q3 2010?

Reported stock-position changes between this filing and the previous one.

Stock value

$3.25B

Positions

Estimated turnover

32.5%

Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.

New positions

ALRAlere Inc$161.71Mreported value+5.23M shares VRSKVerisk Analytics, Inc.$28.01Mreported value+1.00M shares PLCMPolycom Inc$17.73Mreported value+650.0K shares ALR 3 PERP BAlere Inc$10.78Mreported value+49.0K shares

Increased positions

VRXValeant Pharmaceuticals International, Inc.$675.35Mreported value+11.82M shares+78.1%VRSNVeriSign Inc/ca$375.55Mreported value+420.2K shares+3.7%BCRC.r. Bard, Inc.$345.82Mreported value+1.30M shares+44.3%WTWWillis Towers Watson Plc$266.81Mreported value+939.4K shares

Reduced positions

ITGartner, Inc.$494.30Mreported value-4.00M shares-19.2%

Exited positions

IMAInverness Medical Innovations, Inc.$139.39Mprior reported value-5.23M shares-100.0%NTYNbty Inc$49.81Mprior reported value-1.46M shares-100.0%IMA-PBInverness Medical Innovations, Inc.$9.52Mprior reported value-48.3K shares-100.0%